Hypertension in CKD Market, By Drug Class (Diuretics, RAS Blockade, Beta-Blockers, Calcium Channel Blockers, Others ), By Distribution Channel, By Geography

Description

The Global Hypertension in CKD Market is estimated to be valued at US$ 254.2 Mn in 2023 and is expected to exhibit a CAGR of 10.7% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 254.2 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	10.70%	2030 Value Projection:	US$ 517.6 Mn

Figure 1. Global Hypertension in CKD Market Share (%), By Drug Class 2023

Chronic kidney disease (CKD) is a common cause of and a result of uncontrolled hypertension. The interaction between hypertension and CKD is complex and increases the risk of adverse cardiovascular and cerebrovascular outcomes. The pathophysiology of hypertension in CKD is complex, with multiple factors contributing, including decreased nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nervous system overactivity, hormone activation, including the renin-angiotensin-aldosterone system, and endothelial dysfunction. Hypertension in Chronic Kidney Disease (CKD) patients is treated with drug classes such as diuretics, RAS blockade, β - blockers, calcium channel blockers. According to the Centre for Disease Control and Prevention, in 2022 more than 1 in 7 U.S. adults-about 35.5 Mn people, or 14% of the U.S. population are estimated to have CKD. Growing prevalence of CKD is increasing the demand for new drugs and medicines and Key players are actively involved in increasing their research and developmental activities and clinical trials, which are expected to bolster thw growth of Hypertension in CKD Market

Market Dynamics

The Key players are indulged in collaborating in order to conduct clinical trials for different diseases. For instance, on June 12, 2023, Novartis AG, a global pharmaceutical company, announced an agreement to acquire Chinook Therapeutics, a clinical-stage biotechnology company developing precision medicines for kidney diseases with an innovative medicine strategy and renal pipeline. Moreover, increasing product launches by key players is expected to drive growth of the market over the forecast period. For instance, on January 24, 2023, Boehringer Ingelheim International GmbH, a Germany-based global pharmaceutical company, announced U.S. Food and Drug Administration (FDA) approval for phase III trial for Jardiance, which is being investigated to reduce the risk of kidney disease progression or cardiovascular death in adults with CKD.

Key features of the study:

This report provides an in-depth analysis of the global hypertension in CKD market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global hypertension in CKD market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG., C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd., KBP Biosciences Holdings Limited, Ardelyx, Reata Pharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd, Pfizer Inc., Bayer Pharmaceuticals, Inc, GSK plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global hypertension in CKD market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hypertension in CKD market

Global Hypertension in CKD Market Detailed Segmentation:

By Drug Class:
- Diuretics
- RAS Blockade
- β-Blockers
- Calcium Channel Blockers
- Others (α-Blockers, Vasodilators, Proteinuria, etc.)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles
- Sanofi S.A
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- AstraZeneca Plc
- Novartis International AG
- C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd.
- KBP Biosciences Holdings Limited
- Ardelyx
- Reata Pharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd
- Pfizer Inc.
- Bayer Pharmaceuticals, Inc
- GSK plc.

Product Code: CMI4431

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Key Developments
Pipeline analysis
Regulatory Scenario
Key Developments
Treatment Approaches
PEST Analysis

4. Global Hypertension in CKD Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Hypertension in CKD Market, By Drug Class, 2018 - 030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
RAS Blockade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
β-Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Others (α-Blockers, Vasodilators, Proteinuria, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

6. Global Hypertension in CKD Market, By Distribution Channel, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)

7. Global Hypertension in CKD Market, By Region, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 -2030, (US$ Mn)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Company Profiles
- Sanofi S.A
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Teva Pharmaceutical Industries Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Eli Lilly and Company
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- AstraZeneca Plc
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Novartis International AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- KBP Biosciences Holdings Limited
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Ardelyx
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Reata Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Kissei Pharmaceutical Co., Ltd
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Pfizer Inc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Bayer Pharmaceuticals, Inc
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- GSK plc.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies

9. Section

References
Research Methodology
About us and Sales Contact